PLRX Stock Analysis: Buy, Sell, or Hold?
PLRX - Pliant Therapeutics, Inc. Common Stock
$1.05
0.00 (0.48%)
▲
5d:
-3.24%
30d:
-10.68%
90d:
-12.92%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
2d
Get Alerted When PLRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PLRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PLRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PLRX is currently trading at $1.04, which is considered oversold relative to its 30-day fair value range of $1.07 to $1.15.
Technical Outlook: Technically, PLRX is in a strong downtrend. The price is currently testing key support at $1.04. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PLRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $2.50 (+140.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PLRX is in a strong downtrend. The price is currently testing key support at $1.04. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PLRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $2.50 (+140.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.07 -
$1.15
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 140.4% below Wall St target ($2.50)
Trading Range Analysis
30-Day Trading Range
$1.07 -
$1.15
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.28
(26.8%)
Support & Resistance Levels
Support Level
$1.04
Resistance Level
$1.12
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.29
Wall Street Target
$2.50
(+140.4%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 03, 2026 3:12 PM ET
Data refreshes hourly during market hours. Next update: 4:12 PM
Data refreshes hourly during market hours. Next update: 4:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 54 HOLD |
